Financhill is a comprehensive financial analysis platform that provides stock analysis, market data, investment tools, and educational resources to help investors make informed decisions.

How do I get started with Financhill?

You can start by creating a free account, exploring our stock analysis tools, setting up a watchlist, or trying our 7-day trial for full access to all premium features.

What features does Financhill offer?

Financhill offers stock analysis, technical charts, fundamental data, earnings information, dividend tracking, portfolio management, market screening tools, and educational resources.

What are 10K annual reports?

10K reports are comprehensive annual reports filed by public companies with the SEC, containing detailed financial statements, business operations, risk factors, and management discussion.

How often are annual reports updated?

Annual reports are typically filed once per year, usually within 60-90 days after the company's fiscal year end. We update our database as soon as new reports become available.

How do I analyze CMA stock?

Use our comprehensive analysis tools including technical charts, fundamental metrics, earnings data, and Stock Score to evaluate CMA investment potential.

What is CMA stock price today?

Get real-time CMA stock price, historical data, and price charts on Financhill. Track CMA performance with our advanced analysis tools.

Is CMA a good investment?

Evaluate CMA investment potential using our Stock Score, fundamental analysis, technical indicators, and earnings data. Consider your risk tolerance and investment goals.

How to buy CMA stock?

To buy CMA stock, open a brokerage account, research the company using our analysis tools, and place your order through your broker. Always do your own research before investing.

What is the market cap of CMA?

View detailed market capitalization data and company valuation metrics for CMA on our comprehensive analysis page.

What is the P/E ratio of CMA?

Use our fundamental analysis tools to view CMA P/E ratio and compare valuation metrics with industry peers.

What are CMA earnings?

View CMA earnings data, quarterly results, revenue growth, and profit margins on our comprehensive earnings analysis page. Track earnings trends and analyst estimates.

Back

Comerica, Inc. 10K Form

Buy

CMA
Comerica, Inc.

Last Price:

$84.13

Seasonality Move:

3.02%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2024-04-26	10Q	CMA/Comerica, Inc. Quarterly
2024-02-28	10K	CMA/Comerica, Inc. Annual
2023-10-30	10Q	CMA/Comerica, Inc. Quarterly
2023-07-26	10Q	CMA/Comerica, Inc. Quarterly
2023-04-28	10Q	CMA/Comerica, Inc. Quarterly
2023-02-14	10K	CMA/Comerica, Inc. Annual

Receive CMA News And Ratings

See the #1 stock for the next 7 days that we like better than CMA

CMA Financial Statistics

Sales & Book Value

Annual Sales:	$4.8B
Cash Flow:	$-302M
Price / Cash Flow:	462.98
Annual Sales:	$55.15
Price / Book:	1.53

Profitability

EPS (TTM):	5.22570
Net Income (TTM):	$713M
Gross Margin:	$0
Return on Equity:	10.11%
Return on Assets:	0.91%

Comerica, Inc. Earnings Forecast

Key Comerica, Inc. Financial Ratios

The Gross Profit Margin over the past 38 years for CMA is 0.00%.
The Selling, General & Administrative Expenses for CMA have been equal to 0.00% of Gross Profit Margin.
The Interest Expense is 73.63% of Operating Income.
The Net Earning history of CMA is 14.33% of Total Revenues.
Per Share Earnings over the last 41 years have been positive in 27 years.

Comerica, Inc. Stock Price Chart

Industry, Sector and Symbol

Stock Exchange:	S&P500
Industry:	Banks
Sector:	Financials
Current Symbol:	CMA
CUSIP:	200340
Website:	comerica.com

Debt

Debt-to-Equity Ratio:	0.73
Current Ratio:	0.25
Quick Ratio:	0

Price-to-Earnings

Trailing P/E Ratio:	16.8
Forward P/E Ratio:	15.45

CMA Technical Analysis vs Fundamental Analysis

Buy

Comerica, Inc. (CMA) is a Buy

Is Comerica, Inc. a Buy or a Sell?

Comerica, Inc. stock is rated a Buy

The current Comerica, Inc. [CMA] share price is $84.12. The Score for CMA is 68, which is 36% above its historic median score of 50, and infers lower risk than normal.